Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…
HOME > REGULATORY
REGULATORY
- PMDA to Add 4 Staff to Expand Orphan Designation Program: FY2023 Budget
December 26, 2022
- MHLW’s FY2023 Budget Totals 33.2 Trillion Yen
December 26, 2022
- Japan Cabinet OKs Record Social Security Budget for FY2023
December 26, 2022
- MHLW Panel OKs 70 More Health Damage Claims for COVID-19 Vaccines
December 26, 2022
- Japan’s Reform Timeline Sees Major Updates for Text on Drug Pricing Overhaul
December 23, 2022
- Japan Deregulation Panel Proposes Two-Step Approval Scheme for SaMD
December 23, 2022
- PMDA to Develop Overseas PR Strategy to Woo Overseas Biotechs
December 23, 2022
- MHLW to Issue Development Requests for New Indications for 6 Meds including Stivarga
December 23, 2022
- Chuikyo Reps in Face-Off over Medical Fees to Address Drug Supply Disruptions
December 22, 2022
- Japan to Cut 310 Billion Yen in Drug Spending in FY2023 Off-Year Revision: Ministers
December 22, 2022
- Special PMP Increase to Offset 95% of Price Cuts for 150 Products: FY2023 Revision
December 22, 2022
- Japan Designates Antibiotics as Key Resources for Economic Security
December 21, 2022
- LDP Health Panel OKs FY2023 Budget Plan; MHLW Gives “Low 300-Billion-Yen Range” for Drug Cost Cut
December 20, 2022
- Still No Serious Safety Concerns with COVID-19 Vaccines: MHLW Panels
December 20, 2022
- LDP Lawmakers Give Certain Credit to FY2023 Price Revision Plan
December 20, 2022
- Susmed’s Insomnia App in Line for Approval as Early as January
December 20, 2022
- Healthcare Providers Rap Product Coverage of Off-Year Re-Pricing, Payers Hail Threshold: Chuikyo
December 19, 2022
- Orphan Drug Tag Granted for Takeda’s Maralixibat and More
December 19, 2022
- Ruling Parties OK FY2023 Tax Reform Outline; No More Special COVID Measure for R&D Credits
December 19, 2022
- Chuikyo OKs FY2023 Price Revision Outline Specifying “0.625 Times” Product Coverage Threshold
December 19, 2022
ページ
Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
The Liberal Democratic Party (LDP) will wrap up its discussions on the FY2023 tax reform plan within a few days. Some provisions of the R&D tax credit system, which allow drug makers to deduct a portion of R&D expenses from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…